LaRosa J
George Washington University Medical Center, Washington, D.C.
Cardiology. 1989;76 Suppl 1:55-61; discussion 61-4. doi: 10.1159/000174547.
Both alone and in combination with other lipid-lowering drugs, the bile acid sequestrants cholestyramine and colestipol, are excellent agents for lowering circulating low-density lipoprotein (LDL) cholesterol levels. They have been shown to lower the incidence of new coronary events and to retard the progression of coronary atherosclerosis. They also induce qualitative changes in lipoproteins whose significance requires further investigation but may be of significance in coronary disease prevention. While side effects may be bothersome for some patients, they can generally be managed effectively. In particular, modest lowering of dosage may preserve considerable LDL cholesterol lowering and virtually eliminate side effects. Sequestrants appear to be among the safest and most effective drugs in the cholesterol-lowering armamentarium.
胆汁酸螯合剂考来烯胺和考来替泊单独使用或与其他降脂药物联合使用时，都是降低循环中低密度脂蛋白（LDL）胆固醇水平的优秀药物。它们已被证明可降低新的冠状动脉事件的发生率，并延缓冠状动脉粥样硬化的进展。它们还会引起脂蛋白的质性变化，其意义有待进一步研究，但可能对冠心病预防具有重要意义。虽然副作用可能会给一些患者带来困扰，但通常可以有效控制。特别是，适度降低剂量可能在保持相当程度降低LDL胆固醇的同时，几乎消除副作用。螯合剂似乎是降胆固醇药物中最安全、最有效的药物之一。
